Agilent Technologies, Inc. (NYSE:A) Shares Purchased by Bailard Inc.

Bailard Inc. boosted its position in shares of Agilent Technologies, Inc. (NYSE:A) by 4.4% during the second quarter, Holdings Channel.com reports. The firm owned 2,613 shares of the medical research company’s stock after buying an additional 111 shares during the quarter. Bailard Inc.’s holdings in Agilent Technologies were worth $339,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Quantbot Technologies LP purchased a new position in Agilent Technologies during the first quarter worth about $938,000. Cetera Investment Advisers increased its holdings in Agilent Technologies by 953.3% in the 1st quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock valued at $4,757,000 after purchasing an additional 29,590 shares during the last quarter. UBS Group AG raised its position in Agilent Technologies by 84.5% in the fourth quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock valued at $45,281,000 after purchasing an additional 149,159 shares during the period. TD Asset Management Inc raised its position in Agilent Technologies by 27.1% in the fourth quarter. TD Asset Management Inc now owns 1,609,420 shares of the medical research company’s stock valued at $223,758,000 after purchasing an additional 343,175 shares during the period. Finally, iA Global Asset Management Inc. lifted its stake in Agilent Technologies by 26.2% during the first quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock worth $3,168,000 after purchasing an additional 4,523 shares in the last quarter. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Trading Down 0.3 %

Shares of Agilent Technologies stock opened at $140.50 on Tuesday. The company’s fifty day moving average is $134.34 and its two-hundred day moving average is $138.65. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15. The company has a market capitalization of $40.99 billion, a P/E ratio of 33.22, a PEG ratio of 4.86 and a beta of 1.05.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the previous year, the firm posted $1.43 EPS. The firm’s revenue for the quarter was down 5.6% on a year-over-year basis. Analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the transaction, the chief executive officer now owns 25,185 shares in the company, valued at approximately $3,274,050. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the sale, the senior vice president now directly owns 49,486 shares in the company, valued at $6,595,494.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The disclosure for this sale can be found here. Insiders sold 20,874 shares of company stock worth $2,811,770 over the last 90 days. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Evercore ISI lifted their target price on Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a research report on Thursday, August 22nd. Citigroup raised their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. UBS Group boosted their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Stifel Nicolaus reissued a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday. Finally, Jefferies Financial Group reissued a “hold” rating and set a $135.00 price objective (down previously from $152.00) on shares of Agilent Technologies in a report on Monday, June 3rd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.80.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.